Novo Nordisk A/S - share repurchase programme
22 Juli 2024 - 2:22PM
UK Regulatory
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo
Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour
Rules"). This programme is part of the overall share repurchase
programme of up to DKK 20 billion to be executed during a 12-month
period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.2 billion in the
period from 7 May 2024 to 5 August 2024.
Since the announcement 15 July 2024, the following transactions
have been made:
|
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
|
Accumulated, last announcement |
1,697,820 |
|
1,623,066,660 |
| 15 July
2024 |
36,968 |
980.84 |
36,259,639 |
| 16 July
2024 |
37,000 |
972.00 |
35,963,993 |
| 17 July
2024 |
37,999 |
930.48 |
35,357,395 |
| 18 July
2024 |
37,500 |
916.73 |
34,377,441 |
| 19 July
2024 |
37,500 |
907.23 |
34,020,989 |
|
Accumulated under the programme |
1,884,787 |
|
1,799,046,117 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
11,984,827 B shares of DKK 0.10 as treasury shares, corresponding
to 0.3% of the share capital. The total amount of A and B shares in
the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 19 July 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 10,619,037 B shares at an average share
price of DKK 878.31 per B share equal to a transaction value of DKK
9,326,780,889.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to
drive change to defeat serious chronic diseases, built upon our
heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs
about 66,000 people in 80 countries and markets its products in
around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit
novonordisk.com, Facebook,
Instagram, X, LinkedIn
and YouTube.
Contact for further information.
| Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
|
Investors: |
|
Jacob Martin
Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David Heiberg
Landsted
+45 3077 6915
dhel@novonordisk.com
|
Mark Joseph
Root (US)
+1 848 213 3219
mjhr@novonordisk.com
|
Sina
Meyer
+45 3079 6656
azey@novonordisk.com
|
Frederik Taylor
Pitter
+45 3075 8259
fptr@novonordisk.com |
Ida Melvold
Gjøsund
+45 3077 5649 idmg@novonordisk.com |
- 20240722 Share repurchase CA
- 20240722 Share repurchase transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
